Fourth, we used capivasertib, an AKT inhibitor currently approved for breast cancer treatment [39], and observed that capivasertib could significantly reduce T163pMcl-1 and Mcl-1 levels without affecting S159pMcl-1 (Fig. 6D). Here, MCL1 is linked to breast cancer.